Specify a stock or a cryptocurrency in the search bar to get a summary
Baudax Bio Inc
BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. Address: 490 Lapp Road, Malvern, PA, United States, 19355
Analytics
WallStreet Target Price
24 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BXRX
Dividend Analytics BXRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BXRX
Stock Valuation BXRX
Financials BXRX
Results | 2019 | Dynamics |